Clinical Trial to Evaluate the Efficacy and Safety of Monotherapy Group of HL1113R1 or HL1113R2 Versus HL1113 (Fixed Dose Combination) in Patients With Essential Hypertension and Type II Diabetes Mellitus
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 228 participants.
Also called NCT07552389
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 228 participants
- Sponsor
- Registry
-
NCT07552389
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- South Korea
- Registry status
- Recruiting
Technical summary
Registry record NCT07552389. Randomized; quadruple masking; primary purpose treatment. Start 2025-12-18 (actual); primary completion 2028-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Clinical Trial to Evaluate the Efficacy and Safety of Monotherapy Group of HL1113R1 or HL1113R2 Versus HL1113 (Fixed Dose Combination) in Patients With Essential Hypertension and Type II Diabetes Mellitus
- Condition
- Hypertension
- Condition
- Diabete Type 2
- Intervention (Drug)
- Test group
- Intervention (Drug)
- Exploratory test group
- Intervention (Drug)
- Control group 1
- Intervention (Drug)
- Control group 2
- Lead sponsor
- Hanlim Pharm. Co., Ltd.
Record details
- Record id
cardio:ct-nct07552389- Content hash
424a995397d59353de0aff1a0bdeeb8208937fbdaf4ba3ad52a53a883f3e4ccd